💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Judge declines to block Colorado from banning medication abortion reversal

Published 04/28/2023, 05:53 PM
Updated 04/28/2023, 06:00 PM
© Reuters. FILE PHOTO: Used boxes of Mifepristone, the first pill in a medical abortion, line a trash can at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 20, 2023. REUTERS/Evelyn Hockstein

By Brendan Pierson

(Reuters) - A federal judge in Denver on Friday rejected a Catholic medical center's bid to block Colorado from banning an unproven treatment meant to reverse the effects of a medication abortion drug.

U.S. District Judge Daniel Domenico said there was no need to block the first-of-its-kind ban because the state has said it will not enforce it for now, meaning that the center, Bella Health and Wellness, is not under any immediate threat. He did not address the merits of the case.

"Our clients are glad they can continue caring for women who ask for help after taking the first abortion pill," Rebekah Ricketts, a lawyer with the conservative legal group Becket Fund for Religious Liberty representing Bella, said in an email.

Medication abortion begins with the drug mifepristone, which blocks action of the hormone progesterone, crucial for sustaining pregnancy, and is completed with a second drug, misoprostol. Proponents of medication abortion reversal say that if a woman changes her mind after taking mifepristone but before taking misoprostol, the pregnancy can be continued by administering a high dose of progesterone.

There are no large controlled studies of the treatment, and the American College of Obstetricians and Gynecologists has said that its safety and efficacy are unsupported.

Colorado Governor Jared Polis, a Democrat, signed a law on April 14 that would subject health care practitioners who perform medication abortion reversal to discipline unless the state's medical licensing boards determine that treatment is a "generally accepted standard of practice." They also could potentially lose their licenses

The law gives the boards until October to make that determination and issue formal rules, and the state has said it will not enforce the ban until that rulemaking process is complete.

Bella filed its lawsuit the same day the law was signed. It alleges that the law violates the U.S. Constitution's guarantee of free exercise of religion, free speech and equal protection.

© Reuters. FILE PHOTO: Used boxes of Mifepristone, the first pill in a medical abortion, line a trash can at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 20, 2023. REUTERS/Evelyn Hockstein

Mifepristone is the subject of a heated legal battle as anti-abortion groups seek to pull it from the market. A maker of mifepristone is challenging state restrictions on it in West Virginia and a group of doctors is challenging restrictions in North Carolina.

Republican state legislatures have also taken steps to restrict access to the drug, while Democratic legislatures have sought to protect it.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.